February 2022 – Page 204 – 1stOncology™: Cancer Intelligence Service

Synthetic TLR-3 ligands

On February 1, 2022 Tollys Presented the Corporate Presentation (Presentation, Tollys, FEB 1, 2022, View Source [SID1234607551])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Targovax and Prof. Michael Uhlin at Karolinska Institutet enter research collaboration

On February 1, 2022 Targovax ASA (OSE: TRVX), a clinical-stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, reported that it has entered into a two-year research collaboration with Prof. Michael Uhlin of the Department of Clinical Science, Intervention and Technology at Karolinska Institutet in Stockholm, Sweden, to develop and characterize novel ONCOS oncolytic viruses (Press release, Targovax, FEB 1, 2022, View Source [SID1234607550]).

Dr. Uhlin is a professor of clinical immunology at Karolinska Institutet specializing in onco-immunology, transplantation and lymphocyte biology. Under the collaboration agreement with Targovax, Prof. Uhlin will establish and coordinate a research team dedicated to pre-clinical in vitro and in vivo evaluation of novel ONCOS oncolytic adenoviruses, including circular RNA delivery vectors. The research collaboration has an initial term of two years, which may be extended if successful.

Dr. Victor Levitsky, Chief Scientific Officer of Targovax, said: "Prof. Uhlin is a highly accomplished scientist with deep experience in translational and clinical immunology. His expertise and research capabilities will play a critical role as we build our portfolio of next generation ONCOS constructs over the coming years. To achieve our ambitious goals of expanding into novel immunotherapy mechanisms, such as circular RNA delivery, access to high-caliber scientists with the relevant skill-set and state-of-the-art infrastructure will be essential. This is precisely what we get through this collaboration with the Karolinska Institute."

Prof. Michael Uhlin, Group Leader at the Department of Clinical Science, Intervention and Technology at Karolinska Institutet, added: "The team at Targovax has generated a compelling set of clinical data for their lead candidate ONCOS-102, which they are now applying to enhance their platform with next generation armed viral immunotherapies. I find it highly scientifically interesting to support Targovax in understanding the biology and immunological activity of this innovative class of oncolytic delivery vectors. It will be exciting to participate in the characterization and optimization of novel ONCOS candidates as potential future treatment options for patients with challenging solid tumors".

Summary of Consolidated Financial Results [Japanese GAAP] For the Third Quarter of the Fiscal Year Ending March 31, 2022

On January 28, 2022 Nippon Kayaku reported that Summary of Consolidated Financial Results [Japanese GAAP] For the Third Quarter of the Fiscal Year Ending March 31, 2022 (Press release, Nippon Kayaku, FEB 1, 2022, View Source [SID1234607549])

1. Consolidated Business Results for the First Three Quarters of the Fiscal Year Ending March 31, 2022 (April 1, 2021–December 31, 2021)
(2) Consolidated Financial Position

2. Status of Dividends3. Consolidated Business Results Forecasts for the Fiscal Year Ending March 31, 2022 (April 1, 2021–March 31, 2022)

Notes
(1) Significant changes in subsidiaries during the first three quarters (changes in designated subsidiaries that result in changes in scope of consolidation): None
(2) Adoption of special accounting methods for presenting the quarterly consolidated financial statements: None
(3) Changes to accounting policies and estimates and restatements

[1] Changes to accounting policies associated with revision of accounting standards or similar items: Yes
[2] Changes other than
[1]: None
[3] Changes to accounting estimates: None
[4] Restatements: None Note: See

"2. Quarterly Consolidated Financial Statements and Notes to Quarterly Consolidated Financial Statements,
(3) Notes to Quarterly Consolidated Financial Statements (Changes to Accounting Policies)" on page 8 for further details.
(4) Number of shares issued (common stock)
[1] Number of shares issued at end of the fiscal period (including treasury stock) As of December 31, 2021: 177,503,570 shares As of March 31, 2021: 177,503,570 shares
[2] Number of treasury stock at end of the fiscal period As of December 31, 2021: 9,257,789 shares As of March 31, 2021: 6,710,650 shares
[3] Average number of shares during the fiscal period (cumulative) First three quarters of fiscal year ending March 31, 2022: 169,174,386 shares First three quarters of fiscal year ended March 31, 2021: 170,793,503 shares

*Quarterly summary financial statements are not subject to audit by a certified public accountant or audit firm. *Analysis related to appropriate use of the business results forecasts, and other notes (Disclaimer concerning forward-looking statements) The information in this report constitutes forward-looking statements regarding future events and performance.

This information is based on the beliefs and assumptions of management in light of information currently available to it at the time of announcement and subject to a number of uncertainties that may affect future results. Actual business results may differ substantially from the forecasts herein due to various factors. For matters pertaining to business forecasts, please refer to
"(3) Analysis of Forward-looking Statements, Including Consolidated Business Forecasts" on page 3 of the Supplementary Information.

Lupin and Axantia Enter into a License, Supply and Technology Sharing Agreement for Pegfilgrastim in the Middle East and North Africa

On February 1, 2022 Global pharma major, Lupin Limited (Lupin) reported that they have entered into a License, Supply and Technology Sharing agreement with Axantia Holding (Axantia), a leading pharmaceutical company in the region operating through its pharmaceutical subsidiaries; Pharma International Company and Med City Pharmaceutical Industries (Press release, Lupin, FEB 1, 2022, View Source [SID1234607548]). Under the terms of Agreement, Axantia will register, distribute and market biosimilar Pegfilgrastim Drug Product in certain territories including Saudi Arabia, certain GCC countries, Jordan, Lebanon, Iraq, Sudan, Libya and Algeria.

Lupin had earlier received the U.S. FDA acceptance for review of the Biologics License Application (BLA) for its proposed biosimilar to Neulasta (pegfilgrastim) through a filing using the 351(k) pathway.

Pegfilgrastim is indicated to reduce the duration of neutropenia and the incidence of febrile neutropenia in patients receiving chemotherapy.

EISAI RECEIVES THE TOKYO GOVERNOR PRIZE FOR CORPORATE GOVERNANCE OF THE YEAR® 2021

On February 1, 2022 Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") reported that it was selected as the winner of the Tokyo Governor Prize for Corporate Governance of the Year 2021, which is an award program organized by the Japan Association of Corporate Directors (JACD; Chairman: Yoshihiko Miyauchi) (Press release, Eisai, FEB 1, 2022, View Source [SID1234607547]). The award ceremony was held on January 31, 2022.

The awards have been established to recognize the companies which have achieved and maintained the medium to long term profitability by implementing good corporate governance, since 2015. Among the eligible companies for selection of the Corporate Governance of the Year 2021, the Tokyo Governor Prize goes to a company which has excellent corporate governance and also practices ESG activities such as environmental activities, women empowerment, initiatives for diversity and work style reforms.

Commenting on the reason for selecting Eisai, Mr. Eiichiro Kodama, Director General for Global Financial City Strategy, Office of the Governor for Policy Planning, Tokyo Metropolitan Government stated, "Eisai is a pioneer in incorporating its corporate philosophy into the Articles of Incorporation and practicing "Purpose Management." With regard to corporate governance, Eisai makes the most of its status as a company with a nomination committee, etc., system to clearly separate management oversight and business execution, and places great importance to dialogue with its stakeholders including patients. In terms of ESG, Eisai is a signatory to the United Nations Global Compact and actively participates in climate change-related initiatives such as "RE100" and the Japan Climate Initiative. In addition, Eisai is taking on the challenge of quantifying values that do not appear on the balance sheet, such as investments in human capital, with attempting to select KPIs related ESG including the ratio of women in management positions, analyze its relationship with PBR (Price Book-value Ratio), and utilize the verification results for engagement with investors. Eisai is actively working to tell the story of the cause-and-effect relationship between the ESG initiatives and the enhancement of corporate value, thus taking on the extremely important challenge to visualize invisible value, embody the value of ESG, and disseminate them."

Eisai defines its corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides" in the Articles of Incorporation, and shares it with its stakeholders. Eisai calls this philosophy the human health care (hhc) philosophy, in one word, and believes that practicing philosophical management based on the hhc philosophy will contribute to achieving Sustainable Development Goals (SDGs) and further enhance its corporate value.

Eisai is committed to further strengthening its corporate governance in order to realize the hhc philosophy.

1stOncology is recognized as a
Top 10 Global Pharma Analytic Provider

Continue your journey with 1stOncology by accessing our Free Leading Cancer Conference Whitepapers, signing up for our Free Weekly Newsletter and requesting a Free Demo to see how we can help you be 1st in Oncology!

Month: February 2022

Synthetic TLR-3 ligands

Targovax and Prof. Michael Uhlin at Karolinska Institutet enter research collaboration

Summary of Consolidated Financial Results [Japanese GAAP] For the Third Quarter of the Fiscal Year Ending March 31, 2022

Lupin and Axantia Enter into a License, Supply and Technology Sharing Agreement for Pegfilgrastim in the Middle East and North Africa

EISAI RECEIVES THE TOKYO GOVERNOR PRIZE FOR CORPORATE GOVERNANCE OF THE YEAR® 2021